MCM7、Ki-67、ER、PR在乳腺癌中的表达及其与新辅助化疗关系的研究  

Study of the expressions of MCM7,Ki-67,ER,PR and their relationship with neoadjuvant chemotherapy in breast cancer

作　　者：戴文斌[1] 任占平[1] 罗殿中[2] 黄平[3] 任珊[1] 石喆[1] 

机构地区：[1]柳州市人民医院病理科,广西柳州545006 [2]广西医科大学研究生院,广西南宁530021 [3]柳州市人民医院乳腺外科,广西柳州545006

出　　处：《华夏医学》2013年第6期1087-1090,共4页Acta Medicinae Sinica

基　　金：广西自然科学基金(桂科自0991270)

摘　　要：目的:探讨乳腺癌新辅助化疗前后MCM7、Ki-67、ER、PR蛋白的表达,并分析其与化疗疗效的关系。方法:采用免疫组化法检测55例乳腺癌新辅助化疗前后标本中MCM7、Ki-67、ER、PR的表达。结果:新辅助化疗有效率为76.4%。化疗前MCM7和Ki-67蛋白阳性表达均显著高于化疗后(P<0.01),而化疗前后ER和PR蛋白阳性表达差异均无统计学意义(P>0.05)。化疗有效组MCM7蛋白阳性表达显著高于无效组(P<0.01),而Ki-67蛋白表达差异无统计学意义(P>0.05);化疗有效组ER和PR蛋白阳性表达均显著低于无效组(P<0.05)。结论:ET方案新辅助化疗对乳腺癌有较好的疗效,化疗后MCM7、Ki-67蛋白表达下降。MCM7高表达,ER和(或)PR阴性者化疗更为敏感,3者可能作为指导乳腺癌化疗并预测化疗敏感性的分子生物学指标。Objective： To investigate the expressions of MCM7, Ki-67, ER, PR before and after the neoadjuvant chemotherapy in breast cancer patients, and to analyze the relationship with the effect of neoadjuvant chemotherapy. Methods： The expressions of MCMT, Ki-67, ER and PR before and after the neoadjuvant chemotherapy were examined by immunohistochemistry in 55 cases of breast cancer. Results： The overall effective rate of the neoadjuvant chemotherapy was 76.4%. The positive protein expressions of MCM7 and Ki-67 before the neoadjuvant chemotherapy were si higher than those after the neoadjuvant chemotherapy（P〈0. 01）, but there were no gnificantly significant differences in the protein expressions of ER and PR（P〈0.05）. The positive protein expression of MCM7 in the effective neoadjuvant chemotherapy group was significantly higher than that of the ineffective neoadjuvant chemotherapy group （P〈0.01）, but there was no statistical difference in the protein expression of Ki-67 （P〈0.05）. The positive protein expressions of ER and PR in the effective neoadjuvant chemotherapy group were significantly lower than those of the ineffective neoadjuvant chemotherapy group （P〈0.05）. Conclusions： Neoadjuvant chemotherapy with ET regimen is effective in treating breast cancer and the expressions of MCM7 and Ki-67 decreased after the neoadjuvant chemotherapy. Patients with high expression of MCMT, negative ER or PR are more likely to respond to the chemotherapy. The used as blological markers for guiding combination of chemotherapy the expressions of MCM7, ER and PR can be and prediction in patients with breast cancer.

关 键 词：乳腺癌 新辅助化疗 MCM7 KI-67 ER PR 

分 类 号：R737.9[医药卫生—肿瘤]